Table 1 Clinical characteristics of 35 patients with CAEBV
From: Outcome of L-DEP regimen for treatment of pediatric chronic active Epstein–Barr virus infection
No. of patients (%) or median of clinical features (range) | |
|---|---|
Gender | |
Male | 15 (42.8%) |
Female | 20 (57.2%) |
Median age at diagnosis (year) | 7.0 (2.5–17.5) |
EBV infection time before diagnosis (month) | 3 (1–60) |
Fever | 31 (88.6%) |
Splenomegaly | 31 (88.6%) |
Hepatomegaly | 29 (82.9%) |
Lymphadenopathy | 35 (100%) |
Skin lesions | 9 (25.7%) |
Coronary artery dilatation | 4 (11.4%) |
With HLH | 22 (62.9%) |
WBC (× 109/l) | 4.67 (0.95–12.2) |
Neutrophil (× 109/l) | 1.89 (0.27–6.72) |
Hb (g/l) | 104 (83–133) |
PLT (× 109/l) | 189 (39–515) |
Albumin (g/l) | 36.7 (21.6–44.8) |
AST (U/l) | 80.4 (13.8–1314.0) |
ALT (U/l) | 60.3 (9.8–1275.3) |
Bilirubin (μmol/l) | 10.43 (3.81–99.83) |
Triglyceride (mmol/l) | 1.90(0.58–4.09) |
Fibrinogen (g/l) | 2.12 (0.84–34.1) |
Ferritin(ng/ml) | 146.9 (24.7–4353.00) |
NK activity (%) | 15.43 (7.80–17.48) |
Level of cytokines | |
IFN-γ (pg/ml) | 12.72 (1.62–769.91) |
TNF-α (pg/ml) | 2.82 (0.00–244.33) |
IL-10 (pg/ml) | 5.31 (1.35–103.42) |
IL-6 (pg/ml) | 32.9 (1.75–2500.00) |
SCD25 | 10,831 (437.0–44,000.0) |
EBV-DNA (copies/ml) | |
In blood | 1.84 × 106 (5.00 × 103–3.96 × 107) |
In plasma | 3.17 × 103 (5.00 × 102–5.30 × 106) |